10.1038/s41598-017-12236-3 378 WangY.VachonE.ZhangJ.CherepanovV.KrugerJ.LiJ.et al (2005)
Covers gastric stability of this 15-aa pentadecapeptide (~1,419 Da), bioavailability differences, formulation challenges, and detection methods
(PubMed) That doesnt automatically translate to healthier, and it certainly doesnt translate to safe to combine with other secretagogues indefinitely. A clinician-friendly framework to evaluate any peptide stack you see online If you want the full decision logic, use Metos pillar: Heres the condensed version Id use in a consult: Step 1: Define the outcome in one sentence Not fat loss. Instead: Reduce visceral adiposity and improve triglycerides in 12 weeks, or Improve return-to-running tolerance after a tendon injury. Step 2: Grade evidence, not enthusiasm Use three buckets: A: Human outcomes evidence (best) B: Human biomarker evidence (useful but indirect) C: Preclinical/mechanistic only (hypothesis) Example: Semaglutide for weight loss: A CJC-1295 for raising IGF-1: B BPC-157/TB-500 for tendon healing: often C low B , depending on claim Step 3: Avoid redundancy If two compounds push the same pathway, youre more likely to get side effects than synergy
Western blotting HTMCs were grown in the above-mentioned TMC medium in five 12-well plates at a density of 5 10 4 /ml for 24 h, and the medium was replaced with a new one, containing 1 l of water (negative control), TGF-1 (20 g/ml) or glucaric acid (10 mM) for 10 min
